Eli Lilly and Company
|Headquarters||Indianapolis, Indiana, U.S.|
|David A. Ricks (
Joshua Smiley ( Vice president & CFO) 
|Revenue||US$22.319 billion (2019) |
|US$5.595 billion (2019) |
|US$8.318 billion (2019) |
|Total assets||US$39.286 billion (2019) |
|Total equity||US$2.699 billion (2019) |
Number of employees
|33,625 (2019) |
|Footnotes / references|
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War. 
Lilly's notable achievements include being the first company to mass-produce the polio vaccine developed by Jonas Salk, and insulin. It was one of the first pharmaceutical companies to produce human insulin using recombinant DNA including Humulin ( insulin medication), Humalog ( insulin lispro), and the first approved biosimilar insulin product in the US, Basaglar ( insulin glargine). 
The company is ranked 123rd on the 2019 Fortune 500.  It is ranked 221st on the Forbes Global 2000 list of the largest public companies in the world  and 252nd on the Forbes list of America's Best Employers. 
Eli Lilly is a full member of the Pharmaceutical Research and Manufacturers of America  and the European Federation of Pharmaceutical Industries and Associations (EFPIA). 
As of 1997, it was the largest corporation and the largest charitable benefactor in Indiana. 
In 1869, after working for drugstores in Indiana, Lilly became a partner in a Paris, Illinois, drugstore with James W. Binford.  In 1873, Lilly left the partnership with Binford and returned to Indianapolis. In 1874, Lilly partnered with John F. Johnston and opened a drug manufacturing operation called Johnston and Lilly, but dissolved the partnership in 1876. Lilly used his share of the assets to open his own pharmaceutical manufacturing business in Indianapolis in May 1876. His new business venture became Eli Lilly and Company.  
On May 10, 1876, Lilly opened his own laboratory in Indianapolis, where he began to manufacture medicinal drugs. The sign outside, above the shop's door, read: "Eli Lilly, Chemist."    Lilly began his manufacturing venture with three employees including Lilly's son, Josiah (J. K.).  
One of the first medicines that Lilly produced was quinine, a drug used to treat malaria.  By the end of 1876, sales reached $4,470.  By 1879, the company had grown to $48,000.  In 1878, Lilly hired his brother, James, as his first full-time salesman and the subsequent sales team marketed the company's drugs nationally. 
The company moved from Pearl Street to larger quarters at 36 South Meridian Street. In 1881, the company moved to its headquarters in Indianapolis's south-side industrial area. Lilly later purchased additional facilities for research and production.  
Lilly's first innovation was gelatin-coating for pills and capsules. The company's other early innovations included fruit flavorings and sugarcoated pills, which made the medicines easier to swallow. 
In 1881, Lilly formally incorporated the business as Eli Lilly and Company, elected a board of directors, and issued stock to family members and close associates.  Colonel Lilly's only son, Josiah (J. K.), a pharmaceutical chemist, graduated from the Philadelphia College of Pharmacy in 1882, and joined the family business as a superintendent of its laboratory after college. J. K. became company president in 1898.  In 1883 the company contracted to mix and sell Succus Alteran, its first widely successful product and one its best sellers. The product was marketed as a "blood purifier" and as a treatment for syphilis, some types of rheumatism, and skin diseases such as eczema and psoriasis.   Sales from this product provided funds for Lilly to expand its manufacturing and research facilities.  By the late 1880s Colonel Lilly was one of the Indianapolis area's leading businessmen, whose company had more than one-hundred employees and had $200,000 ($5,276,296 in 2015 chained dollars) in annual sales. 
As the Lilly company grew, other businesses set up operations near the plant on Indianapolis's near south side. The area developed into one of the city's major business and industrial hubs. Lilly's production, manufacturing, research, and administrative operations in Indianapolis eventually occupied a complex of more than two dozen buildings covering a fifteen-block area, as well as production plants along Kentucky Avenue. 
Around 1890, Colonel Lilly turned over the day-to-day management of the business to his son, J. K., who ran the company for thirty-four years. Although the 1890s were a tumultuous decade economically, the company flourished and came out stronger than ever.   In 1894 Lilly purchased a manufacturing plant to be used solely for creating capsules. The company also made several technological advances in the manufacturing process, including automating its capsule production. Over the next few years the company annually created tens of millions of capsules and pills. 
Until the turn of the century Lilly operated in Indianapolis and the surrounding area as many other pharmaceutical businesses did—manufacturing and selling "sugar-coated pills, fluid extracts, elixirs, and syrups".  The company used plants for its raw materials and produced its products by hand. One historian noted, "Although the Indianapolis firm was more careful in making and promoting drugs than the patent medicine men of the era, the company remained ambivalent about scientific research." 
In addition to Colonel Lilly, his brother, James, and son, Josiah (J. K.), the growing company employed other Lilly family. Colonel Lilly's cousin, Evan Lilly, was hired as a bookkeeper.  As young boys, Lilly's grandsons, Eli and Josiah Jr. (Joe), ran errands and performed other odd jobs. Eli and Joe joined the family business after college. Eventually, each grandson served as company president and chairman of the board. 
Josiah (J. K.), Colonel Lilly's son and Eli and Joe's father, inherited the company after Colonel Lilly died and became its president in 1898.  At the time of Colonel Lilly's death the company had a product line of 2,005 items and annual sales of more than $300,000 ($8,547,600 in 2015 chained dollars).  Colonel Lilly was a pioneer in the modern pharmaceutical industry, with many of his early innovations later becoming standard practice. His ethical reforms in a trade that was marked by outlandish claims of miracle medicines began a period of rapid advancement in the development of medicinal drugs.  J. K. Lilly continued to advocate for federal regulation on medicines.  Under J. K.'s leadership, the company introduced scientific management concepts, organized the company's research department, increased its sales force, and began international distribution of its products.  In addition J. K. oversaw a large expansion of the company. By 1905 the company reached sales of $1 million ($26,381,481 in 2015 chained dollars). 
Just before and after World War I, the Lilly company experienced rapid change.  Expansion of Lilly's manufacturing facilities at the McCarty Street plant improved production capacity with a new Science Building (Building 14), opened in 1911, and a new capsule plant (Building 15) in 1913.  The company also began constructions of the Lilly Biological Laboratories, a research and manufacturing plant on 150 acres near Greenfield, Indiana, in 1913.  
In addition to development of new medicines, the company achieved several technological advances, including automation of its production facilities. Lilly was also an innovator in pill capsule manufacturing. It was among the first manufacturers to insert medications into empty gelatin capsules, which provided a more exact dosage.  Lilly manufactured capsules for its own needs and sold its excess capacity to others.  A 1917 Scientific American article claimed the Lilly operation in Indianapolis was "the largest capsule factory in the world" and was "capable of producing 2.5 million capsules a day".  One of Lilly's innovations was fruit flavoring for medicines and sugar-coated pills to make their medicines easier to swallow.  Over the next few years the company began to create tens of millions of capsules and pills annually. 
Other advances improved plant efficiency and eliminated production errors. Eli Lilly, grandson of the company founder, introduced a method for blueprinting manufacturing tickets in 1909.  This process, which created multiples copies of a drug formula, helped eliminate manufacturing and transcription errors.  In the 1920s Eli introduced the new concept of straight-line production, where raw materials entered at one end of the facility and the finished product came out the other end, in the company's manufacturing process. Under Eli's supervision, the design for Building 22, a new 5-floor plant that opened in Indianapolis in 1926, implemented the straight-line concept to improve production efficiency and lower production costs.   One historian noted, "It was probably the most sophisticated production system in the American pharmaceutical industry."  This more efficient manufacturing process also allowed the company to hire a regular workforce. Instead of recalling workers at peak times and laying them off when production demand fell, Lilly's regular workforce produced less-costly medicines in off-peak times using the same manufacturing facilities. 
During the 1920s the introduction of new products also brought the company financial success.  In 1919 Josiah hired biochemist George Henry Alexander Clowes as director of biochemical research. In 1921 three University of Toronto scientists, J. J. R. Macleod, Frederick G. Banting, and Charles H. Best, were working on the development of insulin for treatment of diabetes.  Clowes proposed a collaboration with the researchers in December 1921, then again March and May 1922. The researchers were hesitant to work with a commercial drug firm, particularly since they had the Connaught Laboratories' non-commercial facilities at hand. Nonetheless, as limits were reached at the scale to which Connaught could produce insulin, Clowes and Eli Lilly met with the researchers in 1922 to negotiate an agreement with the University of Toronto scientists to mass-produce insulin.    The collaboration greatly accelerated the large-scale production of the extract.  In 1923, Lilly began selling Iletin (Insulin, Lilly), their tradename for the first commercially available insulin product in the U.S for the treatment of diabetes.  Numerous objections were registered by the Insulin Committee of the University of Toronto in regard to Lilly's use of the term "Iletin", although production continued under this name and the objection was later dropped "as a concession".  
Banting and Macleod won a Nobel Prize in 1923 for their research, which they subsequently shared with co-discoverers Charles Best and James Collip.   Insulin, "the most important drug" in the company's history, did "more than any other" to make Lilly "one of the major pharmaceutical manufacturers in the world."  Eli Lilly enjoyed effective monopoly on the sale of insulin in the U.S. for almost two years, until the first of the new American licensees, Frederick Stearns & Co., entered the market in June 1924. 
The success of insulin enabled the company to attract well-respected scientists and, with them, make more medical advances. By its fiftieth anniversary in 1926 sales reached $9 million and the company produced more than 2,800 different items.  In 1928 Lilly introduced Liver Extract 343 for the treatment of pernicious anemia, a blood disorder, in a joint venture with two Harvard University scientists, George R. Minot and William P. Murphy. In 1930 Lilly introduced Liver Extract No. 55 in collaboration with George Whipple, a University of Rochester scientist.  Minot, Murphy, and Whipple won the 1934 Nobel Prize in medicine for their research. 
Despite the economic challenges of the Great Depression, Lilly's sales rose to $13 million in 1932.  That same year Eli Lilly, the eldest grandson of Col. Lilly, was named as the company's president to succeed his father, who remained as chairman of the board until 1948. Eli joined the family business in 1909.  In his early years at the company Eli was especially interested in improving production efficiency and introduced a number of labor-saving devices. He also introduced scientific management principles and implemented cost-savings measures that modernized the company.  In addition Eli was involved in expanding the company's research efforts and collaborations with university researchers. 
In 1934, the firm opened two new facilities on the McCarty Street complex: a replica of Lilly's 1876 laboratory and the new Lilly Research Laboratories, "one of the most fully equipped facilities in the world."  In the 1930s the company also continued expansion overseas.  In 1934, Eli Lilly and Company Limited, the company's first overseas subsidiary was established in England, with headquarters in London and a manufacturing plant in Basingstoke.  
World War II brought production at Lilly to a new high with the manufacturing of Merthiolate and penicillin. During the war Lilly also cooperated with the American Red Cross to process blood plasma and by war's end the company had dried over two million pints of blood, "about 20 percent of the United States' total".  Merthiolate, first introduced in 1930, was an "anticeptic and germicide" that became a U.S. army "standard issue" during World War II.   In the early 1940s Lilly became one of the companies mass-producing penicillin. 
International operations expanded even further during World War II.  Eli Lilly International Corp. was formed in 1943 as a subsidiary to encourage business trade abroad. By 1948 Lilly employees worked in thirty-five countries, most of them as sales representatives in Latin America, Asia, and Africa. 
At the end of World War II the company continued to grow. In 1945, Lilly began a major expansion effort that would include two manufacturing operations in Indianapolis. The company purchased the massive Curtiss-Wright propeller plant on South Kentucky Avenue, west of the company's McCarty Street operation. When renovation was completed in mid-1947, the Kentucky Avenue location manufactured antibiotics and capsules and housed the company's shipping department.  By 1948 Lilly employed nearly 7,000 people. 
Eli Lilly, who had served as the company's president since 1932, retired from active management of the company in 1948, became chairman of the board, and relinquished the presidency to his brother, Josiah K. Lilly, Jr. (Joe).  During Eli's sixteen-year presidency sales rose from $13 million in 1932 to $117 million in 1948. Joe joined the company in 1914 and concentrated on the company's personnel and marketing efforts.  He served as company president from 1948 to 1953, then became chairman of the board and remained in that capacity until his death in 1966.  In 1952 the company offered its first public shares of stock.  In 1953, Eugene N. Beesley was named the company's new president, the first non-family member to run the company. 
Over the next several decades Lilly continued to develop and introduce new drugs to the marketplace. In the 1950s, Lilly introduced two new antibiotics: vancomycin and erythromycin. In addition Lilly was heavily involved in production and distribution of Jonas Salk's poliomyelitis (polio) vaccine. In 1954, the National Foundation for Infantile Paralysis (NFIP) contracted with five pharmaceutical companies to produce Salk's polio vaccine for clinical trials. These included Lilly as well as Parke, Davis and Company, Cutter Laboratories, Wyeth Laboratories, and Pitman-Moore Company.  Lilly's selection to produce the vaccine was, in part, due to its previous experience in collaborations with university researchers.  Lilly manufactured 60 percent of the Salk vaccine in 1955.
During the mid-twentieth century Lilly continued to expand its production facilities outside of Indianapolis. In 1950 Lilly began Tippecanoe Laboratories in Lafayette, Indiana,  and increased antibiotic production with its patent on erythromycin. In 1954 Lilly formed Elanco Products Company for the production of veterinary pharmaceuticals. In 1969, the company opened a new plant in Clinton, Indiana. 
After a company reorganization and transition to non-family management in 1953, Lilly continued to expand its global presence. In the 1960s Lilly operated thirteen affiliate companies outside the United States.  In 1962, with an acquisition from Distillers Company, the company established a major factory in Liverpool, England. In 1968, Lilly built its first research facility, the Lilly Research Centre Limited, outside the United States near London, England in Surrey.
During the 1970s and 1980s, Eli Lilly and Company saw a flurry of drug production: an antibiotic, Keflex, in 1971; a heart drug, Dobutrex, in 1977; Ceclor, which would become the world's top selling oral antibiotic, in 1979;[ peacock term] a leukemia drug, Eldisine; an antiarthritic, Oraflex; and an analgesic, Darvon. When generic drugs flooded the marketplace after the expiration of patents for drugs discovered in the 1950s and 1960s, Lilly diversified into other areas, most notably agricultural chemicals, animal-health products, cosmetics, and medical instruments.
In 1971, the company became a component of the S&P 500 Index.
To further diversify its product line, Lilly made an uncharacteristic, but ultimately profitable move in 1971, when it bought cosmetic manufacturer Elizabeth Arden, Inc. for $38 million. Although the subsidiary continued to lose money for five years after Lilly acquired it, executive management changes at Arden helped turn it into a financial success. By 1982 the subsidiary's "sales were up 90 percent from 1978, with profits doubling to nearly $30 million." Sixteen years after its acquisition, Lilly sold Arden to Fabergé in 1987 for $657 million. 
In 1977, Lilly ventured into medical instruments with the acquisition of IVAC Corporation, which manufactures vital signs and intravenous fluid infusion monitoring systems.  Lilly also purchased Cardiac Pacemakers Incorporated, a manufacturer of heart pacemakers in 1977. In 1980, Lilly acquired Physio-Control Corporation. Other acquisitions included Advance Cardiovasular Systems Incorporated in 1984, Hybritech in 1986, and Devices for Vascular Intervention, Incorporated in 1989. Lilly acquired Pacific Biotech in 1990 and Origin Medsystems and Heart Rhythm Technologies, Incorporated in 1992. In the early 1990s, Lilly combined these medical equipment companies into a Medical Devices and Diagnostics Division that "contributed about 20 percent" of Lilly's annual revenues.[ citation needed]
In 1989, a joint agri-chemical venture between Elanco Products Company and Dow Chemical created DowElanco. In 1997, Lilly sold its 40% share in the company to Dow Chemical for $1.2 billion and the name was changed to Dow AgroSciences. 
In 1994, Lilly acquired PCS Systems, a drug delivery business for Health Maintenance Organizations, and later added two similar organizations to its holdings.  Lilly purchased PCS, which was the largest U.S. prescription drug benefits manager at the time, for $4 billion. 
In 1991, Vaughn Bryson was named CEO of Eli Lilly. During his 20-month tenure, the company reported its first quarterly loss as a publicly traded company.  In 1993, Randall L. Tobias, a vice-chairman of AT&T Corporation and Lilly board member, was named Lilly's chairman, president, and CEO after "product and competitive pressures" had "steadily eroded Lilly's stock price since early 1992."  Tobias was the first president and CEO recruited from outside of the company. Under Tobias's leadership the company "cut costs and narrowed its mission".  Lilly sold companies in its Medical Device and Diagnostics Division, expanded international sales, made new acquisitions, and funded additional research and product development. Sidney Taurel, former chief operating officer of Lilly, was named CEO in 1998, replacing Tobias. Taurel was named chairman in January 1999. In 2000, Lilly reported $10.86 billion in net sales.
In 1998, Eli Lilly formed a joint venture with Icos Corporation (ICOS), a Bothell, Washington-based biotechnology company, to develop and commercialize Cialis, a product for the treatment of erectile dysfunction. In October 2006, Lilly announced its intention to acquire Icos for $2.1 billion, or $32 per share.  After its initial attempt to acquire Icos failed under pressure from large institutional shareholders, Lilly revised its offer to $34 per share. Institutional Shareholder Services (ISS), a proxy advisory firm, advised Icos shareholders to reject the proposal as undervalued,   but the buyout was approved by Icos shareholders and Lilly completed its acquisition of the company on January 29, 2007.   Lilly closed Icos manufacturing operations, terminated nearly 500 Icos employees, and left 127 employees working at the biologics facility.  In December 2007, CMC Biopharmaceuticals A/S (CMC), a Copenhagen, Denmark-based provider of contract biomanufacturing services, bought the Bothell-based biologics facility from Lilly and retained the existing 127 employees.   
In January 2009, the largest criminal fine in U.S. history, totaling $1.415 billion was imposed on Lilly for illegal marketing of its best-selling product, the atypical antipsychotic medication, Zyprexa. 
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced their global agreement for the joint development and marketing of new APIs for diabetes therapy. Lilly could receive more than one billion dollars for their work on the project, while Boehringer Ingelheim could receive more than $800 million from development of the new drugs.  Oral anti-diabetic of Boehringer Ingelheim– Linagliptin and BI 10773–and two insulin analogs of Lilly–LY2605541 and LY2963016–were in phase II and III of clinical developmentat that time. 
In April 2014, Lilly announced plans to buy Swiss drugmaker Novartis AG's animal health business for $5.4 billion in cash to strengthen and diversify its Elanco unit. Lilly said it planned to fund the deal with about $3.4 billion of cash on hand and $2 billion of loans.  As a condition of the acquisition, the Sentinel heartworm treatment would be divested to Virbac in order to avoid a monopoly in a subsector of the heartworm ( Dirofilaria immitis) treatment market. 
In March 2015, the company announced it would join Hanmi Pharmaceutical in developing and commercialising Hanmi's phase I Bruton's tyrosine kinase inhibitor HM71224 in a deal which could yield $690 million.  A day later the company announced another deal with Innovent Biologics to co-develop and commercialise at least three of Innovents treatments over the next decade, in a deal which could generate up to $456 million. As part of the deal the company will contribute its c-Met monoclonal antibody whilst Innovent will contribute a monoclonal antibody which targets CD-20. The second compound from Innovent is a preclinical immuno-oncology molecule.  The following week the company announced it would restart its collaboration with Pfizer surrounding the Phase III trial of Tanezumab. Pfizer is expected to receive an upfront sum of $200 million from the company.  In April 2015, the company engaged CBRE Group to sell its biomanufacturing facility in Vacaville, California.  The facility resides on a 52 acres (0.21 km2) campus and is one of the largest biopharmaceutical manufacturing centers in the United States. 
In January 2017, Elanco Animal Health, a subsidiary of the company completed the acquisition of Boehringer Ingelheim Vetmedica, Inc's (a subsidiary of Boehringer Ingelheim) US feline, canine and rabies vaccines portfolio. 
In May 2018, the company acquired Armo Biosciences for $1.6 billion.  Days later the company announced it would acquire Aurora kinase A inhibitor developer - AurKa Pharma - and control over the lead compound, AK-01, for up to $575 million.  
In January 2019, Eli Lilly announced it would acquire Loxo Oncology for $235 per share - valuing the business at around $8 billion - significantly expanding the business' oncology offerings. The deal will give Eli Lilly Loxo's oral TRK inhibitor, Vitrakvi (larotrectinib), LOXO-292, an oral proto- oncogene receptor tyrosine kinase rearranged during transfection (RET) inhibitor, LOXO-305, an oral Bruton's tyrosine kinase (BTK) inhibitor and LOXO-195, a follow-on TRK inhibitor.   In August 2019, Elanco acquired the Bayer animal health business for $7.6 billion.  
In January 2020, the company announced its acquisition of Dermira for $1.1 billion, gaining control of two key assets, among others; lebrikizumab and glycopyrronium cloth used to treat hyperhidrosis.    In June, the company announced it had begun the world's first study of a potential monoclonal antibody treatment for COVID-19, with a Phase 1 trial of LY-CoV555, in collaboration with AbCellera.  On October 7, 2020, Eli Lilly announced that its cocktail was effective and that it had filed with the Food and Drug Administration for an emergency use authorization (EUA).  This was the same day that rival company Regeneron also filed for an EUA for its own monoclonal antibody treatment.  In October, Eli Lilly announced it would acquire Disarm Therapeutics at its experimental treatments for axonal degeneration, via SARM1 inhibitors, for $135 million (plus a further $1.225 billion based on regulatory and commercial milestones).  In October, Eli Lilly announced that the National Institutes of Health (NIH) ACTIV-3 clinical trial evaluating its monoclonal antibody, bamlanivimab (LYCoV555), found that bamlanivimab was not effective in treating people hospitalized with COVID-19.  Other studies, including the NIH ACTIV-2 trial and its own BLAZE-1 trial, will continue to evaluate bamlanivimab.  In November, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.   In December, Lilly announced it would acquire Prevail Therapeutics Inc for $1 billion, boosting its pipeline in neurodegenerative disease gene therapies. 
Eli Lilly and Company has a long history of collaboration with research scientists. In 1886 Ernest G. Eberhardt, a chemist, joined the company as its first full-time research scientist.  Lilly also hired two botanists, Walter H. Evans and John S. Wright, to join its early research efforts.   After World War I the company's expanded production facilities and introduction of new management methods set the stage for Lilly's next crucial phase—its "aggressive entry into scientific research and development."  The first big step came in 1919 when Josiah Lilly hired biochemist George Henry Alexander Clowes as director of biochemical research.  Clowes had extensive medical research expertise and links to the scientific research community, which led to the company's collaborations with researchers in the U.S. and elsewhere.  Clowes's first major collaboration with researchers who developed insulin at the University of Toronto significantly impacted the company's future.  Lilly's success with insulin production secured the company's position as a leading research-based pharmaceutical manufacturer, allowing it to attract and hire more research scientists and to collaborate with other universities in additional medical research.  In 1934 the company built a new research laboratory in Indianapolis.  As part of its research and product development process Lilly also conducted clinical studies at Indianapolis City Hospital (Wishard Memorial Hospital). Lilly continues to conduct clinical studies to test medications before their introduction to the market.  In 1949 Eli Lilly actually went into partnership with the United States Army Reserve setting up a local Strategic Intelligence Research and Analysis (SIRA)Unit to allow employees to research company data for the Scientific Logistics and Eurasian fields of study (source: declassified Defense Intelligence Agency document MDR -0191-2008 dated 17 Sep 2012). In 1998 the company dedicated new laboratories for clinical research at the Indiana University Medical Center in Indianapolis.
In addition to internal research and development activities, Lilly is also involved in publicly funded research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox, a collaboration with pharmaceutical companies, research organizations, and the European Commission to improve the safety of drugs.   In 2008 this consortium, which included Lilly S.A. (Switzerland), secured an €8 million budget for a 40-month project that was coordinated by the European Federation of Pharmaceutical Industries and Associations ( EFPIA), an organization who represents the research-based pharmaceutical industry and biotech companies operating in Europe.    In 2008 Lilly's activities included research projects within the framework of the Innovative Medicines Initiative, a public-private research initiative in Europe that is a joint effort of the EFPIA and the European Commission.   
The company's most important products introduced prior to World War II included insulin, which Lilly marketed as Iletin (Insulin, Lilly), Amytal, Merthiolate, ephedrine, and liver extracts.  Introduced in 1923, Iletin (Insulin, Lilly) was Lilly's first commercial insulin product. In 2002 the company was the leading producer of products for those with diabetes.[ citation needed]
During World War II Lilly produced penicillins and other antibiotics. In addition to penicillin, other wartime production included "antimalarials," blood plasma, encephalitis vaccine, typhus and influenza vaccine, gas gangrene antitoxin, Merthiolate, and Iletin (Insulin, Lilly). 
Among the company's more recent pharmaceutical developments are cephalosporin, erythromycin, and Prozac (fluoxetine), a selective serotonin reuptake inhibitor (SSRI) for the treatment of clinical depression. Ceclor, introduced in the 1970s, was an oral cephalosporin antibiotic. Prozac, introduced in the 1980s, quickly became the company's best-selling product for treatment of depression, but Lilly lost its U.S. patent protection for this product in 2001. Among other distinctions, Lilly is the world's largest manufacturer and distributor of medications used in a broad range of psychiatric and mental health-related conditions, including clinical depression, generalized anxiety disorder, narcotic addiction, insomnia, bipolar disorder, schizophrenia, and others.[ citation needed]
Eli Lilly has focused on patent-protected medicines, with generic manufacturers taking over production of earlier drugs whose patents have expired.
In 2003, Eli Lilly introduced Cialis (tadalafil), a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours, causing it sometimes to be dubbed the "weekend pill". Cialis was developed in a partnership with biotechnology company Icos Corporation. On December 18, 2006, Lilly bought Icos in order to gain full control of the product. 
Another Lilly manufactured anti-depressant, Cymbalta, a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.[ citation needed]
In 1996, the U.S. Food and Drug Administration approved Gemzar for the treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.[ citation needed]
Eli Lilly was the first distributor of methadone in the United States, an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.[ citation needed] Eli Lily was able to acquire the right to produce the drug commercially for just $1 because the patent rights of the original patent holders, IG Farben and Farbwerke Hoechst, were not protected after the Allies of World War II seized all German patents, research records and trade names. Eli Lilly introduced the drug to the United States in 1947, marketed under the trade name "Dolophine". 
Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. Prozac was approved by the U.S. FDA in 1987 for use in treating depression, with generic versions appearing after 2002.
Eli Lilly has manufactured Secobarbital, a barbiturate derivative with anaesthetic, anticonvulsant, sedative and hypnotic properties. Lilly marketed Secobarbital under the brand name Seconal. Secobarbital is indicated for the treatment of epilepsy, temporary insomnia and as a pre-operative medication to produce anaesthesia and anxiolysis in short surgical, diagnostic, or therapeutic procedures which are minimally painful. With the onset of new therapies for the treatment of these conditions, Secobarbital has been less utilized, and Lilly ceased manufacturing it in 1999.[ citation needed]
Secobarbital gained considerable attention during the 1970s, when it gained wide popularity as a recreational drug. On September 18, 1970, rock guitarist legend Jimi Hendrix died from a secobarbital overdose. On June 22, 1969, secobarbital overdose was the cause of death of actress Judy Garland. The drug was a central part of the plot of the hugely popular novel Valley of the Dolls (1966) by Jacqueline Susann in which three highly successful Hollywood women each fall victim, in various ways, to the drug. The novel was later released as a film by the same name.[ citation needed]
Eli Lilly has developed the vaccine preservative thiomersal (also called merthiolate and thimerosal). Thiomersal is effective by causing susceptible bacteria to autolyze. Launched in 1930, merthiolate was a mercury-based antiseptic and germicide that "had been formulated at the University of Maryland with support of a Lilly research fellowship." 
Zyprexa ( Olanzapine) (for schizophrenia and bipolar disorder, as well as off-label uses) Released in 1996, (see criminal prosecution section) it was the company's best selling drug through 2010, when the patent expired. 
After three generations of Lilly family leadership under company founder, Col. Eli Lilly, his son, Josiah K. Lilly Sr., and two grandsons, Eli Lilly Jr. and Josiah K. Lilly Jr., the company announced a reorganization in 1944 that prepared the way for future expansion and the eventual separation of company management from its ownership.  The large, complex corporation was divided into smaller groups headed by vice presidents and in 1953 Eugene N. Beesley was named the first non-family member to become the company's president. 
Although Lilly family members continued to serve as chairman of the board until 1969, Beesley's appointment began the transition to non-family management.  In 1972 Richard Donald Wood  became Lilly's president and CEO after the retirement of Burton E. Beck.  In 1991 Vaughn Bryson became president and CEO  and Wood became board chairman.  During Bryson's 20-month tenure as Lilly's president and CEO, the company reported its first quarterly loss as a publicly traded company. 
Randall L. Tobias, a vice chairman of AT&T Corporation, was named chairman, president, and CEO in June 1993. Tobias, a Lilly board member since 1986, was recruited from outside the company's executive ranks  first to replace Lilly's president and CEO, Vaughn Bryson, at Bryson's predecessor and then board chairman Richard Wood's urging and then, in short order, also Wood.  Tobias later became the U.S. director of Foreign Assistance and administrator of the U.S. Agency for International Development (USAID), with the rank of ambassador. 
Sidney Taurel, former chief operating officer of Lilly, was named CEO in July 1998 to replace Tobias, who retired. Taurel became chairman of the board in January 1999.  Taurel retired as CEO on March 31, 2008, but remained as chairman of the board until December 31, 2008. John C. Lechleiter was elected as Lilly's CEO and president, effective April 1, 2008. Lechleiter had served as Lilly's president and chief operating officer since October 2005.  In July 2016 Dave Ricks, who also had a long career at Lilly, was appointed CEO. 
In 2006, Fortune magazine named Eli Lilly and Company one of the top 100 companies in the United States for which to work. Also in 2006, Barron's Magazine named the company among the top 500 best managed companies in the U.S.
In 2012, Working Mothers magazine named Lilly one of the "100 Best Companies for Working Mothers" for the eighteenth consecutive year. Working Mother reported that in 2012 forty-eight percent of Lilly's U.S. employees and thirty-four percent of its U.S. managers and executives were women.  
In 2018, Eli Lilly and Company was recognized as one of the Ethisphere Institute's World's Most Ethical Companies, the second year in a row. 
The Lilly family as well as Eli Lilly and Company has a long history of community service. Around 1890 Col. Lilly turned over operation of the family business to his son, Josiah, who ran the company for the next several decades.  Col. Lilly remained active in civic affairs and assisted a number of local organizations, including the Commercial Club of Indianapolis, which later became the Indianapolis Chamber of Commerce,  and the Charity Organization Society, a forerunner to the Family Services Association of Central Indiana, an organization supported by United Way.   Josiah's sons, Eli and Joe, were also philanthropists who supported numerous cultural and educational organizations. 
It was Josiah Sr. who continued his father's civic mindedness and began the company tradition of sending aid to disaster victims.  Following the 1906 San Francisco earthquake, the company sent much needed medicine to support recovery efforts and provided relief after the 1936 Johnstown Flood. 
In 1917, Lilly Field Hospital 32, named in Josiah's honor, was equipped in Indianapolis and moved overseas to Contrexville, France, during World War I, where it remained in operation until 1919.  Throughout World War II, Lilly manufactured more than two hundred products for military use, including aviator survival kits and seasickness medications for the D-Day invasion.  In addition Lilly dried more than two million pints of blood plasma by the war's end. 
The Eli Lilly and Company Foundation, which is separate from the Lilly Endowment, operates as a tax-exempt private charitable foundation that the company established in 1968. The Foundation is funded through Lilly's corporate profits. 
Eli Lilly has been involved in several controversies, including political and medical ethics controversies. Eli Lilly is now the sole manufacturer of BGH having purchased the rights to manufacture the drug from Monsanto.
A landmark study found that fluoxetine (Prozac) was more likely to increase overall suicidal behavior. 14.7% of the patients (n = 44) on fluoxetine had suicidal events, compared to 6.3% in the psychotherapy group and 8.4% from the combined treatment group.  Eli Lilly, the manufacturer, and the lead researcher did not make these findings obvious.  Several internal documents, which were released by the British Medical Journal, indicated a link between use of Prozac and suicidal or violent behavior. The FDA has warned that Prozac and similar antidepressants could cause agitation, panic attacks and aggression.  These documents revealed that Eli Lilly knew about this as early as 1984, years before the drug was FDA-approved. 
In September 2013, Eli Lilly sued Canada for violating its obligations to foreign investors under the North American Free Trade Agreement by allowing its courts to invalidate patents for two of its drugs. The company sought damages in the amount of $500 million for lost potential profits. 
In 2009, four sales representatives for Eli Lilly filed separate qui tam lawsuits against the company for illegally marketing olanzapine (branded Zyprexa), an antipsychotic medication, for uses not approved by the Food and Drug Administration. Eli Lilly pleaded guilty to actively promoting Zyprexa for off-label uses, particularly for the treatment of dementia in the elderly. The $1.415 billion penalty included an $800 million civil settlement and a $515 million criminal fine. The US Justice Department said the criminal fine of $515 million was the largest ever in a healthcare case and the largest criminal fine for an individual corporation ever imposed in a US criminal prosecution of any kind.   "That was a blemish for us," John C. Lechleiter, CEO of Lilly, told The New York Times. "We don't ever want that to happen again. We put measures in place to assure that not only do we have the right intentions in integrity and compliance, but we have systems in place to support that."  In an internal email, Lechleiter had stated "we must seize the opportunity to expand our work with Zyprexa in this same child-adolescent population" for off-label use. 
In January 2019, lawmakers from the United States House of Representatives sent letters to Eli Lilly and other insulin manufacturers asking for explanations for their rapidly raising insulin prices. The annual cost of insulin for people with type 1 diabetes in the U.S. almost doubled from $2,900 to $5,700 over the period from 2012 to 2016. 
- "Eli Lilly and Company 2019 Annual Report". lilly.com. Eli Lilly. 19 February 2020.
- "Eli Lilly and Company Annual Report (Form 10-K)". last10k.com. U.S. Securities and Exchange Commission. February 2019.
- HannahBlake (29 July 2013). "A history of... Eli Lilly & Co -". pharmaphorum.com. Retrieved 14 May 2020.
- Swiatek, Jeff (28 December 2015). "10 all-time greatest Eli Lilly drugs". The Indianapolis Star.
- "Fortune 500: Eli Lilly". Fortune.
- "Forbes: The World's Biggest Public Companies". Forbes.
- "Forbes: America's Best Employers". Forbes.
- "Members". Pharmaceutical Research and Manufacturers of America. Retrieved 14 February 2019.
- "SDG Group Customers: Eli Lilly". SDG Group. Archived from the original on 14 November 2017. Retrieved 13 November 2017.
- Price, Nelson (1997). Indiana Legends: Famous Hoosiers from Johnny Appleseed to David Letterman. Carmel, Indiana: Guild Press of Indiana. p. 58. ISBN 978-1-57860-006-9.
- "Eli Lilly & Company" (PDF). Indianapolis: Indiana Historical Society. p. 1. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- David J. Bodenhamer and Robert G. Barrows, eds. (1994). The Encyclopedia of Indianapolis. Bloomington and Indianapolis: Indiana University Press. p. 911. ISBN 978-0-253-31222-8.CS1 maint: extra text: authors list ( link)
- "Colonel Eli Lilly (1838–1898)" (PDF). Lilly Archives. January 2008. Retrieved 24 October 2016.
- James H. Madison (1989). Eli Lilly: A Life, 1885–1977. Indianapolis: Indiana Historical Society. p. 6. ISBN 978-0-87195-047-5.
- Bodenhamer and Barrows, p. 540.
- The Indiana Historical Society recreated a replica of the first Lilly laboratory on Pearl Street for its exhibition, "You Are There: Eli Lilly at the Beginning," at the Eugene and Marilyn Glick Indiana History Center in Indianapolis. The temporary exhibition (October 1, 2016, to January 20, 2018) also includes costumed interpreters portraying Colonel Lilly, among others. See "The Man Behind State's Most Successful Startup". Kendallville New Sun. Kendallville, Indiana: KPC News. 9 September 2016. Retrieved 21 October 2016. See also Tom Alvarez, ed. (Fall 2016). "Fall Arts Guide". UNITE Indianapolis. Indianapolis: Joey Amato: 32. Retrieved 24 October 2016.CS1 maint: extra text: authors list ( link)
- Price, Indiana Legends, p. 59.
- Price, Indiana Legends, p. 57.
- E. J. Kahn (1975). All In A Century: The First 100 Years of Eli Lilly and Company. West Cornwall, CT. p. 23. OCLC 5288809.
- "Eli Lilly & Company" (PDF). p. 1 and 4. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- Madison, Eli Lilly, p. 27.
- Bodenhamer and Barrows, eds., p. 913.
- James H. Madison (1989). "Manufacturing Pharmaceuticals: Eli Lilly and Company, 1876–1948" (PDF). Business and Economic History. Business History Conference. 18: 72. Archived from the original (PDF) on 14 May 2013. Retrieved 20 February 2013.
- "Eli Lilly & Company" (PDF). p. 2. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- Robert M. Taylor Jr.; Errol Wayne Stevens; Mary Ann Ponder; Paul Brockman (1989). Indiana: A New Historical Guide. Indianapolis: Indiana Historical Society. p. 423. ISBN 978-0-87195-048-2.
- Price, Indiana Legends, p. 60.
- Fridrun Podczeck; Brian E. Jones (2004). Pharmaceutical Capsules. Chicago: Pharmaceutical Press. pp. 12–13. ISBN 978-0-85369-568-4.
- "Eli Lilly & Company" (PDF). pp. 2, 5 and 6. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- "Eli Lilly & Company" (PDF). Indiana Historical Society. p. 3. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- Bodenhamer and Barrows, eds., p. 912.
- Madison, Eli Lilly, pp. 17–18, 21.
- Madison, Eli Lilly, pp. 51, 112–15.
- "The Pharmaceutical Industry in Indiana" (PDF). Indianapolis: Indiana Historical Society. p. 3. Archived from the original (PDF) on 8 June 2013. Retrieved 20 February 2013.
- Madison, Eli Lilly, p. 30.
- Taylor; et al. Indiana: A New Historical Guide. p. 481.
- "Indiana State Historic Architectural and Archaeological Research Database (SHAARD)" (Searchable database). Department of Natural Resources, Division of Historic Preservation and Archaeology. Retrieved 1 April 2016. Note: This includes Eugene F. Rodman (April 1976). "National Register of Historic Places Inventory Nomination Form: Lilly Biological Laboratories" (PDF). Retrieved 1 April 2016. and Accompanying photographs.
- Madison, "Manufacturing Pharmaceuticals," Business and Economic History, p. 73.
- Madison, Eli Lilly, p. 29.
- Madison, Eli Lilly, p. 46.
- Madison, "Manufacturing Pharmaceuticals," Business and Economic History, p. 74.
- Madison, Eli Lilly, p. 76.
- Bliss, Michael (1984). The Discovery of Insulin. University of Chicago Press. ISBN 9780226058986.
- Rutty, Christopher J. "Connaught Laboratories & The Making of Insulin". Connaught Fund. Retrieved 20 June 2019.
- Madison, Eli Lilly, p. 55–57.
- Roberts, Jacob (2015). "Sickening sweet". Distillations. 1 (4): 12–15. Retrieved 20 March 2018.
- Madison, Eli Lilly, p. 61.
- Bliss, Michael (1984). The Discovery of Insulin. University of Chicago Press. pp. 174–175. ISBN 9780226058986.
- Hutchison, F. Lorne (18 October 1924). "Notes on the history of the Insulin Committee's objection to Lilly's use of the term Iletin". University of Toronto Libraries.
- "Insulin wins a great prize". University of Toronto Libraries. New York, NY: Literary Digest. 8 December 1923.
- "Citation to F. G. Banting and J. J. R. Macleod accompanying the Nobel Prize". University of Toronto Libraries. Stockholm, Sweden: Royal Karolinska Institute. 1923.
- Bliss, Michael (1984). The Discovery of Insulin. University of Chicago Press. p. 181. ISBN 9780226058986.
- Madison, Eli Lilly, p. 66–67.
- Madison, Eli Lilly, p. 67.
- "Eli Lilly & Company" (PDF). Indianapolis: Indiana Historical Society. p. 5. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- Madison, Eli Lilly, p. 28–34.
- Madison, Eli Lilly, p. 62–65.
- Madison, Eli Lilly, p. 91.
- Madison, Eli Lilly, p. 111.
- Madison, Eli Lilly, p. 105.
- Madison, Eli Lilly, p. 65 and 106.
- Madison, James H. (1989). Eli Lilly: A Life, 1885–1977. Indianapolis: Indiana Historical Society. p. 65. ISBN 978-0-87195-047-5.
- Madison, Eli Lilly, p. 107–8.
- Madison, Eli Lilly, p. 110.
- Madison, Eli Lilly, p. 91, 119–20.
- Madison, Eli Lilly, p. 120 and 249.
- Price, Indiana Legends, p. 61.
- "Eugene N. Beesley Dead at 67;Ex‐Chairman of Eli Lilly &Co". The New York Times. 9 February 1976. ISSN 0362-4331. Retrieved 21 July 2020.
- "Polio and Eli Lilly and Company" (PDF). Indianapolis: Indiana Historical Society. p. 5. Archived from the original (PDF) on 8 June 2013. Retrieved 20 February 2013.
- "Polio and Eli Lilly and Company" (PDF). Indianapolis: Indiana Historical Society. p. 6. Archived from the original (PDF) on 8 June 2013. Retrieved 20 February 2013.
- Bodenhamer and Barrows, p. 541.
- "Eli Lilly & Company" (PDF). Indianapolis: Indiana Historical Society. p. 6. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- "Eli Lilly & Company" (PDF). p. 7. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- "Eli Lilly Signs Agreement To Acquire Ivac Corp". The New York Times. 14 October 1977. Retrieved 17 August 2017.
- "Dow to Buy Lilly's 40% Stake in Dow Elanco". Los Angeles Times. Reuters. 16 May 1997.
- "Eli Lilly & Company" (PDF). p. 8. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- Armor, Nancy (31 July 1994). "New Lilly Chief Nurtures Change". Kokomo Tribune. Kokomo, IN.
- Associated Press (26 June 1993). "New Lilly Chief Doesn't Have Own 'Agenda'". Kokomo Tribune. Kokomi, IN. Retrieved 27 October 2015.
- Associated Press (26 June 1993). "Eli Lilly CEO Resigns in Dispute". Kokomo Tribune. Kokomi, IN.
- "Eli Lilly & Company" (PDF). p. 8 and 9. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- "Lilly Increases Offer for Icos; Shareholders' Vote Is Put Off". The New York Times. Associated Press. 19 December 2006. Retrieved 27 February 2013.
- Timmerman, Luke (13 January 2007). "Reject Icos Offer, Holders of Shares Advised". The Seattle Times. Retrieved 16 January 2013.
- Timmerman, Luke (7 November 2006). "Proposed Icos Sale Gets More Criticism: Payouts for Execs Called 'Overkill'". The Seattle Times. Retrieved 16 January 2013.
- James, Andrea (26 January 2007). "Icos Voters Approve Buyout by Eli Lilly". Seattle Post-Intelligencer. Retrieved 16 January 2013.
- "Eli Lilly Completes Icos Takeover". The Seattle Times. 30 January 2007. Retrieved 16 January 2013.
- Tartakoff, Joseph (5 December 2007). "New Owner Will Invest $50 Million in Icos Facility". Seattle Post-Intelligencer. Retrieved 27 February 2013.
- Timmerman, Luke (12 December 2006). "All Icos Workers Losing Their Jobs". The Seattle Times. Retrieved 16 January 2013.
- "Eli Lilly Gets $1.4B Fine for Zyprexa Off-Label Marketing". medheadlines.com. Archived from the original on 28 August 2011. Retrieved 30 August 2011.
- Murphy, Tom (12 January 2011). "Lilly, Boehringer Collaborate on Diabetes Drugs". Anderson Herald Bulletin. Anderson, IN. p. A7.
- "Lilly and Boehringer Ingelheim Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide" (Press release). PRNewswire. 11 January 2011.
- Sen, Arnab (22 April 2014). Warrier, Gopakumar (ed.). "Eli Lilly to buy Novartis' animal health unit for $5.4 billion". Reuters. Retrieved 21 April 2015.
- Bartz, Diane (22 December 2014). Benkoe, Jeffrey; Baum, Bernadette (eds.). "Lilly must divest Sentinel products after FTC nod on Novartis deal". Reuters.
- "Eli Lilly to Co-Develop Hanmi BTK Inhibitor for Up-to-$690M". GEN News Highlights. Mary Ann Liebert, Inc. 19 March 2015. Retrieved 21 April 2015.
- "Lilly Joins Innovent in Up-to-$456M+ Cancer Collaboration". GEN News Highlights. Genetic Engineering & Biotechnology News. 20 March 2015. Retrieved 21 April 2015.
- Philippidis, Alex (23 March 2015). "Pfizer, Lilly to Resume Phase III Tanezumab Clinical Program". GEN News Highlights. Mary Ann Liebert, Inc. Retrieved 21 April 2015.
- "Eli Lilly Biomanufacturing Plant For Sale". Advantage Business Media. 21 April 2015.
- "Elanco Animal Health Completes Acquisition of Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio" (Press release). PRNewswire. 3 January 2017.
- "Lilly to Buy CoLucid for $960M to Acquire Late-Stage Migraine Drug - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN".
- "Lilly Completes Acquisition of CoLucid Pharmaceuticals" (Press release). PRNewswire. 1 March 2017.
- Mishra, Manas (10 May 2018). "Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer..." Reuters. Retrieved 8 June 2018.
- "Lilly Continues Oncology Expansion with Plans to Buy AurKa Pharma for Up to $575M - GEN". GEN. Retrieved 8 June 2018.
- Editorial, Reuters (14 May 2018). "Lilly to buy cancer drug developer AurKa Pharma". Reuters. Retrieved 8 June 2018.
- "Eli Lilly Deepens its Oncology Offerings with an $8 Billion Acquisition of Loxo Oncology".
- "Lilly Announces Agreement to Acquire Loxo Oncology".
- "Elanco to buy Bayer's animal health unit for $7.6 billion". Reuters.
- "Elanco to become No.2 in animal health with $7.6 billion Bayer deal". Reuters. 20 August 2019. Retrieved 17 July 2020.
- "Eli Lilly Bags Dermatology Company Dermira for $1.1 Billion". BioSpace. Retrieved 17 July 2020.
- "Lilly Announces Agreement to Acquire Dermira". BioSpace. Retrieved 17 July 2020.
- "Lilly Completes Acquisition of Dermira". BioSpace. Retrieved 3 March 2020.
- "Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans". Lilly. 1 June 2020. Retrieved 4 June 2020.
- Herper, Matthew (7 October 2020). "Eli Lilly says its monoclonal antibody cocktail is effective against Covid-19". STAT. Retrieved 8 October 2020.
- Thomas, Katie (8 October 2020). "Regeneron Asks F.D.A. for Emergency Approval for Drug That Trump Claimed Cured Him". The New York Times. ISSN 0362-4331. Retrieved 8 October 2020.
- "Lilly Statement Regarding NIH's ACTIV-3 Clinical Trial". Eli Lilly and Company (Press release). 26 October 2020. Retrieved 26 October 2020.
- Rizk, John G.; Forthal, Donald N.; Kalantar-Zadeh, Kamyar; Mehra, Mandeep R.; Lavie, Carl J.; Rizk, Youssef; Pfeiffer, JoAnn P.; Lewin, John C. (November 2020). "Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic". Drug Discovery Today: S1359644620305092. doi: 10.1016/j.drudis.2020.11.025.
- "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19". U.S. Food and Drug Administration (Press release). 9 November 2020. Retrieved 9 November 2020. This article incorporates text from this source, which is in the public domain.
- "Eli Lilly to buy gene therapy developer Prevail in about $1 billion deal". Reuters. 15 December 2020.
- "Lilly Announces Completion of Hypnion Acquisition". PRNewswire. 3 April 2007.
- "Lilly to Acquire ImClone Systems in $6.5 Billion Transaction". PRNewswire. 6 October 2008.
- "Lilly to Acquire SGX Pharmaceuticals". PRNewswire. 8 July 2008.
- "Lilly to Acquire Avid Radiopharmaceuticals". PRNewswire. 8 November 2010.
- "Lilly to Acquire Alnara Pharmaceuticals". PRNewswire. 2 July 2010.
- "Eli Lilly and Company Announces Acquisition of Ivy Animal Health". PRNewswire. 25 May 2007.
- "Lilly to Acquire European Rights to Pfizer Animal Health Assets". PRNewswire. 8 March 2010.
- "Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health". PRNewswire. 14 March 2011.
- "Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp". PRNewswire. 24 January 2012.
- "Elanco Announces Agreement to Acquire Lohmann Animal Health". PRNewswire. 24 February 2014.
- "Eli Lilly & Company" (PDF). p. 1 and 2. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- Eberhardt and Evans were Purdue University graduates. See "Eli Lilly & Company" (PDF). p. 2. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- Madison, Eli Lilly, p. 53.
- Madison, Eli Lilly, p. 55.
- Madison, Eli Lilly, p. 63.
- "Eli Lilly & Company" (PDF). p. 4. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013..
- "Alliances". Basel, Switzerland: Genedata. Retrieved 27 February 2013.[ permanent dead link]
- "InnoMed PredTox Consortium Members Present Preliminary Study Results". Basel, Switzerland: Genedata. 15 May 2008. Archived from the original on 11 April 2013.
- Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. 460. pp. 221–238. doi: 10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
- "InnoMed PredTox Member Organizations". Archived from the original on 26 September 2008. Retrieved 2008-08-25.
- "The Innovative Medicines Initiative". Innovative Medicines Initiative. Retrieved 27 February 2013.
- "IMI 1st Call 2008". Innovative Medicines Initiative. Archived from the original on 21 January 2013. Retrieved 27 February 2013.
- Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 15 October 2009. Retrieved 25 August 2008.
- Madison, Eli Lilly, p. 105–6.
- With its television advertisement for Cialis during the 2004 Super Bowl Halftime Show, Eli Lilly was one of several companies whose costly 2004 Super Bowl Halftime advertisements were largely overshadowed by the Janet Jackson and Justin Timberlake Super Bowl XXXVIII halftime show controversy.[ citation needed]
- Current, John D. Pharmacology for Anesthetists:Anesthetics and Adjuvants. Retrieved 19 July 2019.
- Wilson, Duff (2 October 2010). "Side Effects May Include Lawsuits". The New York Times.
- Madison, Eli Lilly, p. 112.
- Hagerty, James R., "Eli Lilly CEO Richard Wood Oversaw Prozac Launch", Wall Street Journal, May 3, 2020. Retrieved 2020-05-23. (subscription required)
- Associated Press (29 March 1977). "Lilly Director Dies in Hawaii". Anderson Herald. Anderson, IN.
- Associated Press (18 September 1991). "Lilly Move No Big Surprise". Kokomo Tribune. Kokomi, IN.
- "Congressional Record, March 29, 2006, S2546" (PDF).
- "Eli Lilly & Company" (PDF). p. 9. Archived from the original (PDF) on 29 July 2016. Retrieved 26 February 2013.
- Associated Press (19 December 2007). "Lechleiter Named Lilly CEO". Kokomo Tribune. Kokomo, IN. p. A7.
- Armstrong, Drew; Koons, Cynthia (27 July 2016). "Lilly Turns From One Company Veteran to Another for New CEO". Bloomberg.
- "Working Mother Report: Meet the 2012 100 Best Companies". Working Mother. New York: Bonnier Working Mother Media Inc. 35 (6): 46. October–November 2012.
- The company was named one of the top 10 best companies for working mothers in 2004 by Working Mothers magazine.
- "Lilly Among the 2018 World's Most Ethical Companies". Lilly.com. Retrieved 8 June 2018.
- Bodenhamer and Barrows, eds., p. 399.
- Bodenhamer and Barrows, eds., pp. 402–03, 911–12, and 560–61.
- Bodenhamer and Barrows, eds., pp. 910–12.
- Madison, Eli Lilly, p. 205–6.
- Meek, Heather. "Lilly, Eli". LearningToGive.org and the Center on Philanthropy at Indiana University. Retrieved 20 February 2013.
- Vitiello, B; Silva, SG; Rohde, P; Kratochvil, CJ; Kennard, BD; Reinecke, MA; Mayes, TL; Posner, K; May, DE; March, JS (2009). "Suicidal events in the Treatment for Adolescents With Depression Study (TADS)". J Clin Psychiatry. 70 (5): 741–7. doi: 10.4088/JCP.08m04607. PMC 2702701. PMID 19552869.
- "When the Cure Is the Cause: The Case of the Green Hairy Tongue". Retrieved 8 June 2018.
- MarketWatch, CBS. "Eli Lilly in Prozac controversy". Retrieved 8 June 2018.
- "Eli Lilly Prozac Documents: What do They Reveal? - AHRP". 26 October 2006. Retrieved 8 June 2018.
- Stastna, Kazi (13 September 2013). "Eli Lilly files $500M NAFTA suit against Canada over drug patents". CBC. Retrieved 1 April 2015.
- "Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa". 09-civ-038. United States Department of Justice. 15 January 2009.
- "Pharmaceutical Company Eli Lilly to Pay Record $1.415 Billion for Off-Label Drug Marketing" (PDF). United States Attorney, Eastern District of Pennsylvania. United States Department of Justice. 15 January 2009. Archived from the original (PDF) on 17 October 2012.
- Wilson, Duff (2 October 2010). "Side Effects May Include Lawsuits". The New York Times. Retrieved 23 September 2011.
- Berenson, Alex (15 March 2008). "Eli Lilly E-Mail Discussed Unapproved Use of Drug". The New York Times. Retrieved 24 August 2015.
- Abutaleb, Yasmeen (30 January 2019). "U.S. lawmakers request info from insulin makers on rising prices". Reuters. Retrieved 1 February 2019.
- Bodenhamer, David J., and Robert G. Barrows, eds. (1994). The Encyclopedia of Indianapolis. Bloomington and Indianapolis: Indiana University Press. ISBN 978-0-253-31222-8.CS1 maint: multiple names: authors list ( link) CS1 maint: extra text: authors list ( link)
- "Eli Lilly & Company" (PDF). Indiana Historical Society. Archived from the original (PDF) on 29 July 2016. Retrieved 24 October 2016.
- Kahn, E. J. (1975). All In A Century: The First 100 Years of Eli Lilly and Company. West Cornwall, CT. OCLC 5288809.
- Madison, James H. (1989). Eli Lilly: A Life, 1885–1977. Indianapolis: Indiana Historical Society. ISBN 978-0-87195-047-5.
- Madison, James H. (1989). "Manufacturing Pharmaceuticals: Eli Lilly and Company, 1876–1948" (PDF). Business and Economic History. Business History Conference. 18: 72. Archived from the original (PDF) on 14 May 2013. Retrieved 20 February 2013.
- Podczeck, Fridrun; Brian E. Jones (2004). Pharmaceutical Capsules. Chicago: Pharmaceutical Press. ISBN 978-0-85369-568-4.
- Price, Nelson (1997). Indiana Legends: Famous Hoosiers From Johnny Appleseed to David Letterman. Indianapolis: Guild Press of Indiana. ISBN 978-1-57860-006-9.
- Taylor Jr., Robert M.; Errol Wayne Stevens; Mary Ann Ponder; Paul Brockman (1989). Indiana: A New Historical Guide. Indianapolis: Indiana Historical Society. p. 481. ISBN 978-0-87195-048-2.
- Tobias, Randall; Tobias, Todd (2003). Put the Moose on the Table: Lessons in Leadership from a CEO's Journey through Business and Life. Indiana University Press. ISBN 978-0-253-11011-4.
- Weintraut, Linda; Jane R. Nolan. "The Secret Life of Building 314". Traces of Indiana and Midwestern History. Indianapolis: Indiana Historical Society. 8 (3): 16–27.
|Wikimedia Commons has media related to Eli Lilly and Company.|